Comparison of Teneligliptin and Luseogliflozin on Pancreatic β-cell Function
Study Overview
This study aims to compare the effects of two medications, SGLT2 inhibitors (luseogliflozin) and DPP-4 inhibitors (teneligliptin), on pancreatic β-cell function in patients with type 2 diabetes.
Study Details
We conducted a 26-week study with 103 patients who had type 2 diabetes. Participants were randomly assigned to take either luseogliflozin or teneligliptin. The main goal was to measure changes in β-cell function using an oral glucose tolerance test.
Key Findings
- Improvement in β-cell Function: Both medications showed improvements in β-cell function, but luseogliflozin had a more significant effect on reducing β-cell dysfunction compared to teneligliptin.
- Results:
- Luseogliflozin group: Improved from -0.46 to -0.20 (p=0.03)
- Teneligliptin group: Improved from -0.26 to -0.05 (p=0.01)
- Proinsulin/C-peptide Ratio: This ratio decreased in the luseogliflozin group but increased in the teneligliptin group, indicating better β-cell function with luseogliflozin.
Conclusion
Both medications improved β-cell function in patients with type 2 diabetes, but luseogliflozin was more effective at reducing β-cell dysfunction.
Clinical Trial Registration
For more information, visit: Clinical Trial Registration
Value of Clinical Trials
Clinical trials are essential for developing safe and effective treatments. Our AI-driven platform, DocSym, helps integrate clinical standards and research into a user-friendly resource for healthcare providers.
Enhancing Patient Care
In today’s healthcare landscape, efficiency is vital. Our mobile apps assist with scheduling, treatment monitoring, and telemedicine, simplifying patient management and expanding digital services.
Improving Outcomes with AI
By leveraging AI, clinics can streamline workflows, enhance patient outcomes, and reduce paperwork. Discover how we can assist you at aidevmd.com.
